Letter to the Editor Regarding “Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder”

TY - JOUR

T1 - Letter to the Editor Regarding “Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder”

AU - Cree, Bruce A.C.

AU - Greenberg, Benjamin

AU - Cameron, Chris

AU - Weinshenker, Brian G.

N1 - Funding Information: Brian G. Weinshenker receives payments for serving as chair of attack adjudication committees for clinical trials in NMOSD for Alexion, MedImmune, Viela Bio (now Horizon Therapeutics) and UCB Biosciences; consultant with Chugai, Genentech, Roche Pharmaceuticals, and Mitsubishi Tanabe Pharma; and has a patent for NMO-IgG for diagnosis of neuromyelitis optica, with royalties paid by Hospices Civils de Lyon, MVZ Labor PD Dr. Volkmann und Kollegen GbR, Oxford University, and RSR. Benjamin Greenberg received consulting fees from Alexion, Novartis, EMD Serono, Horizon Therapeutics, Genentech/Roche, Greenwhich Biosciences, Axon Advisors, Rubin Anders, ABCAM, Signant, IQVIA, Sandoz, Druggability Technologies, Genzyme, Immunovant, and PRIME Education. He has received grant funding from PCORI, NIH, NMSS, The Siegel Rare Neuroimmune Association, Anokion, Clene Nanomedicine and the Guthy Jackson Charitable Foundation for NMO. He serves as an unpaid member of the board of the Siegel Rare Neuroimmune Association. He receives royalties from UpToDate. Chris Cameron is an employee of EVERSANA, which was hired by Horizon Therapeutics as a consultant. Bruce A.C. Cree reports personal fees for consulting from Alexion, Atara, Autobahn, Avotres, EMD Serono, Horizon, Neuron23, Novartis, Sanofi, Therini and TG Therapeutics and received research support from Genentech. Funding Information: No funding or sponsorship was received for this letter or publication of this letter. All authors participated in this letter’s concept and design, analysis, writing and revisions. Brian G. Weinshenker receives payments for serving as chair of attack adjudication committees for clinical trials in NMOSD for Alexion, MedImmune, Viela Bio (now Horizon Therapeutics) and UCB Biosciences; consultant with Chugai, Genentech, Roche Pharmaceuticals, and Mitsubishi Tanabe Pharma; and has a patent for NMO-IgG for diagnosis of neuromyelitis optica, with royalties paid by Hospices Civils de Lyon, MVZ Labor PD Dr. Volkmann und Kollegen GbR, Oxford University, and RSR. Benjamin Greenberg received consulting fees from Alexion, Novartis, EMD Serono, Horizon Therapeutics, Genentech/Roche, Greenwhich Biosciences, Axon Advisors, Rubin Anders, ABCAM, Signant, IQVIA, Sandoz, Druggability Technologies, Genzyme, Immunovant, and PRIME Education. He has received grant funding from PCORI, NIH, NMSS, The Siegel Rare Neuroimmune Association, Anokion, Clene Nanomedicine and the Guthy Jackson Charitable Foundation for NMO. He serves as an unpaid member of the board of the Siegel Rare Neuroimmune Association. He receives royalties from UpToDate. Chris Cameron is an employee of EVERSANA, which was hired by Horizon Therapeutics as a consultant. Bruce A.C. Cree reports personal fees for consulting from Alexion, Atara, Autobahn, Avotres, EMD Serono, Horizon, Neuron23, Novartis, Sanofi, Therini and TG Therapeutics and received research support from Genentech. This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

PY - 2022/9

Y1 - 2022/9

KW - Aquaporin-4

KW - Eculizumab

KW - Inebilizumab

KW - Matching-adjusted indirect comparison

KW - Network meta-analysis

KW - Neuromyelitis optica spectrum disorder

KW - Randomized controlled trials

KW - Satralizumab

UR - https://www.scopus.com/pages/publications/85133305335

UR - https://www.scopus.com/pages/publications/85133305335#tab=citedBy

U2 - 10.1007/s40120-022-00376-2

DO - 10.1007/s40120-022-00376-2

M3 - Letter

AN - SCOPUS:85133305335

SN - 2193-8253

VL - 11

SP - 1439

EP - 1443

JO - Neurology and Therapy

JF - Neurology and Therapy

IS - 3

ER -